FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome
Go back to FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 5.33 -0.1 (1.84%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.43 | 52 Week High | $18.00 | |||
| Open | $5.36 | 52 Week Low | $6.91 | |||
| Day High | $5.45 | P/E | N/A | |||
| Day Low | $5.23 | EPS | $-0.67 | |||
| Volume | 612,957 | |||||
